Top

A--License to the Intellectual Property (IP) for AlphaVax's proprietary Venezuelan Equine Encephalitis (VEE) -based RNA replicon particle (VRP) system

Active

ALPHAVAX2014Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The U.S. Army Contracting Command at Aberdeen Proving Ground, Natick Contracting Division, seeks to acquire a perpetual license to the intellectual property (IP) for AlphaVax's proprietary Venezuelan Equine Encephalitis (VEE)-based RNA replicon particle (VRP) system. This includes comprehensive rights such as patents, copyrights, trade secrets, software, and related technical data. The VRP technology was developed by AlphaVax using both Government and private funding, granting the Government certain purpose rights but not exclusive rights to technology developed with private funds. AlphaVax remains the sole source capable of providing this specialized technology, as it has uniquely developed and qualified the manufacturing process and product release assays at a small scale, expertise that would be difficult and time-consuming for the Government to replicate independently. Acquiring this license is critical for the Medical Countermeasures Systems (MCS) program to avoid considerable schedule delays—estimated at two years—and mitigate research and development risks associated with creating a similar system from scratch. Interested parties are invited to express their interest and capability to respond by emailing the contracting center before the specified deadline. The contract aligns with the Department of Defense’s intent to leverage innovative technologies developed in partnership with private industry while protecting governmental interests and maintaining efficient program timelines.

General Info

U.S. Army seeks perpetual license for AlphaVax's proprietary VEE VRP technology, ensuring timely program delivery.

Agency

Department Of Defense → W6QK Acc-Apg Natick

NAICS

541711 - Research and Development in Biotechnology

Place of Performance

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PostedJun 16

special-notice

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Defense → W6QK Acc-Apg Natick

ContactsNo contacts available

OfficeNATICK, MA, 01760-5011, USA

Organization / AgencyDepartment Of Defense → W6QK Acc-Apg Natick

Office AddressNATICK, MA, 01760-5011, USA

ContactsNo contact information available

Full Description

The U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, has a requirement in support of the Medical Countermeasures Systems (MCS) to procure a perpetual license to the Intellectual Property (IP) for AlphaVax's proprietary Venezuelan Equine Encephalitis (VEE) -based RNA replicon particle (VRP) system, including but not limited to, patents, rights in inventions (patentable or not), copyrights, trade secrets, mask works, rights in databases and collections, other rights in software, and know-how techniques and other data under the authority of FAR Subpart 6.302-1(a)(2)(ii)(A) and (B). The VRP candidate was developed by AlphaVax with Government and private funds; therefore, the Government has Government Purpose Rights to a portion of the IP, but no rights to the development performed with private funding, nor exclusive rights to technologies developed with Government funds. AlphaVax is the only known source that has improved the existing Government owned VRP technology. AlphaVax is the product developer and, as such, is the only company that has developed and qualified the small-scale manufacturing process and product release assays for this platform. It is estimated that it would cost the Government two (2) years in schedule delays to develop a similar process, while potentially infringing on the existing Alphavax IP. Therefore, a contract to procure the IP for the AlphaVax platform would avoid schedule delays and reduce the research and development risk involved in attempting to develop a separate system. Interested parties may identify their interest and capability to respond to this requirement to the U.S. Army RDECOM Contracting Center, Natick Contracting Division via e-mail to: contact@example.gov no later than 9:00 a.m. on June 23, 2014.